People: Cree Inc (CREE.OQ)
22 Mar 2018
Ms. Anne C. Whitaker is Director of the company. Ms. Whitaker joined the Board of Directors in December 2013. Since September 2014, she has served as the Chief Executive Officer and President and as a member of the Board of Directors of Synta Pharmaceuticals Corp., a publicly traded biopharmaceutical company. She previously served from September 2011 to August 2014 as the President of North America Pharmaceuticals for Sanofi S.A., a global integrated healthcare leader focused on patients’ needs. From September 2009 to September 2011, Ms. Whitaker served as Senior Vice President and Business Unit Head, Cardiovascular, Metabolic and Urology (CVMU) at GlaxoSmithKline plc, a publicly traded pharmaceutical research and development company. From October 2008 to August 2009, she served as Senior Vice President of Leadership and Organization Development, and prior to that served in various leadership positions in GlaxoSmithKline’s commercial organization. Ms. Whitaker began her pharmaceutical career in 1991 as a metabolic disease specialist with Upjohn Company before joining GlaxoSmithKline as a sales representative in 1992.
|Total Annual Compensation, USD||28,846|
|Restricted Stock Award, USD||229,440|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||86,216|
|Fiscal Year Total, USD||344,502|